Intersect ENT gets FDA approval for Propel

08/15/2011 | Medscape (free registration)

The FDA has approved Intersect ENT's Propel, an implantable mometasone furoate delivery system for chronic sinusitis. The device helps prevent postsurgery sinus obstruction, reduce inflammation and curb polyp formation in patients, according to three clinical trials conducted.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC